Spots Global Cancer Trial Database for F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

Official Title: 18F-DCFPyL PET/CT in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-Contributory CT Scans

Study ID: NCT03501940

Conditions

Prostate Adenocarcinoma

PSA Level Greater Than 0.2

PSA Level Greater Than or Equal to Two

PSA Progression

Recurrent Prostate Carcinoma

Interventions

Computed Tomography

Fluorine F 18 DCFPyL

Laboratory Biomarker Analysis

Positron Emission Tomography

Study Description

Brief Summary: This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) to participants with prostate cancer that has come back. Diagnostic procedures, such as fluorine F 18 DCFPyL PET/CT, may help find and diagnose prostate cancer and find out how far the disease has spread.

Detailed Description: PRIMARY OBJECTIVES: I. To evaluate fluorine F 18 DCFPyL (18F-DCFPyL) PET/CT for detection of recurrent prostate cancer after initial therapy in patients with elevated prostate-specific antigen (PSA). OUTLINE: Participants receive fluorine F 18 DCFPyL intravenously (IV). After 60-120 minutes, participants undergo whole body PET/CT. Immediately after the first scan, participants may undergo a second PET/CT without receiving fluorine F 18 DCFPyL. After completion of study, participants are followed up at 24-72 hours.